Physician profile
John Hayes
NPI 1023285228
$29,635.68
in general payments reported to CMS, 2019-2025
15 companies · $15.37 in 2025
The $15.37 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,431 · 2022: $20K · 2023: $8,251 · 2024: $196 · 2025: $15.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,350 · Food and Beverage: $1,273 · Travel and Lodging: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,350.00 |
| Food and Beverage | $1,273.27 |
| Travel and Lodging | $838.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $26,800.66 | 2021-2023 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $833.00 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $766.26 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $319.76 | 2021-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $314.64 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $238.26 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $81.72 | 2022-2024 | Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $56.11 | 2021-2022 | |
| Indivior INC. | $55.53 | 2022-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $49.16 | 2022-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $35.17 | 2023-2024 | Auvelity |
| Corium, LLC | $35.05 | 2023-2024 | Azstarys |
| Lundbeck LLC | $18.65 | 2022 | |
| Bausch Health US, LLC | $16.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.